top of page
  • Ann Tucker

NIDA Directors on the Importance of Patient Preference in Opioid Medication Development

Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA), and Dr. Wilson Compton, Deputy Director of NIDA, recently published a commentary regarding a new study on extended-release injections of buprenorphine. The commentary by NIDA states that patient voices and preferences have often been left out of medication development efforts and that patient preferences and outcomes may serve as an important metric in medication trials. In addition, they NIDA notes that extended-release formulations may have benefits in settings where patients have difficulty accessing consistent care such as justice settings, populations experiencing homelessness, and in rural communities. Read more

3 views0 comments

Recent Posts

See All

U.S. House | This week, the House Oversight and Accountability Committee held a hearing on “Oversight and Reauthorization of the Office of National Drug Control Policy." Dr. Rahul Gupta, ONDCP Directo

DEA [3/22] | In a public safety alert, the DEA said it observed a sharp increase in the trafficking of fentanyl mixed with xylazine, a sedative also known as “Tranq” that has been approved by the Food

bottom of page